The use of the optical imaging agent FG001 led to the detection of additional cancer by optical guidance in patients with high-grade glioma, meeting the primary end point of the phase 2b FG001-CT-001 trial.
FluoGuide Announces FG001 Meets Primary Endpoint in Phase llb Trial in Aggressive Brain Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
All patients receiving FG001 had additional cancer detected by optical guidanceFG001 was safe and well tolerated in all patientsCopenhagen, Denmark – FluoGuide A/S , a pioneer in the cutting-edge.